| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AGY Stock Overview
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments.
Allergy Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.19 |
| 52 Week High | UK£0.41 |
| 52 Week Low | UK£0.16 |
| Beta | 1.44 |
| 1 Month Change | 10.00% |
| 3 Month Change | -12.50% |
| 1 Year Change | -33.62% |
| 3 Year Change | 63.83% |
| 5 Year Change | -33.04% |
| Change since IPO | -74.16% |
Recent News & Updates
Shareholder Returns
| AGY | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 1.3% | -2.6% | 0.03% |
| 1Y | -33.6% | 5.7% | -8.3% |
Return vs Industry: AGY underperformed the UK Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: AGY underperformed the UK Market which returned -9% over the past year.
Price Volatility
| AGY volatility | |
|---|---|
| AGY Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AGY is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AGY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 600 | Manuel Llobet | https://www.allergytherapeutics.com |
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut.
Allergy Therapeutics plc Fundamentals Summary
| AGY fundamental statistics | |
|---|---|
| Market Cap | UK£123.97m |
| Earnings (TTM) | -UK£5.38m |
| Revenue (TTM) | UK£79.00m |
1.6x
P/S Ratio-23.1x
P/E RatioIs AGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGY income statement (TTM) | |
|---|---|
| Revenue | UK£79.00m |
| Cost of Revenue | UK£23.10m |
| Gross Profit | UK£55.89m |
| Other Expenses | UK£61.27m |
| Earnings | -UK£5.38m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 70.75% |
| Net Profit Margin | -6.81% |
| Debt/Equity Ratio | 5.2% |
How did AGY perform over the long term?
See historical performance and comparison